Dikkat Eksikliği ve Hiperaktivite Bozukluğu Olan Çocuklarda Kullanılan Uzun Etkili Metilfenidat Bileşiklerinin ve Atomoksetinin Kardiyak Fonksiyonlar Üzerindeki Etkileri-Reference-Cited by-同舟云学术

Dikkat Eksikliği ve Hiperaktivite Bozukluğu Olan Çocuklarda Kullanılan Uzun Etkili Metilfenidat Bileşiklerinin ve Atomoksetinin Kardiyak Fonksiyonlar Üzerindeki Etkileri

Published:2023-02-28 Issue:1 Volume:6 Page:98-106
ISSN:2717-8994
Container-title:Acta Medica Nicomedia
language:tr
Short-container-title:Acta Med Nicomedia

Author:

MUTLU MIHÇIOĞLU Ajda¹^ORCID,KARA Tayfun²^ORCID

Affiliation:

1. UNIVERSITY OF HEALTH SCIENCES, İSTANBUL BAKIRKÖY DR. SADİ KONUK TRAINING RESEARCH CENTER

2. ALANYA ALAADDIN KEYKUBAT UNIVERSITY, FACULTY OF MEDICINE

Abstract

Objectives: Methylphenidate (MPH) and Atomoxetine (ATX) are most commonly prescribed for the treatment of Attention Deficit And Hyperactivity Disorder (ADHD). Despite their widespread use, there are concerns about their cardiovascular safety. In this study, we aimed to investigate the effects of ADHD medications on cardiac functions. Methods: Forty-six children with ADHD disorder using osmotic-release oral system methylphenidate (OROS-MPH), 46 using extended-release methylphenidate (ER-MPH), and 46 using ATX for at least six months were included in the patient groups. 46 children with normal cardiac findings were included as the control group. All participants were evaluated using a sociodemographic information form, physical examination, 12-channel electrocardiography (ECG), transthoracic 2D echocardiography, Doppler echocardiography, and tissue Doppler imaging (TDI). Results: Statistically significant differences were observed in terms of A wave velocity (p=0,002), E/A (p

Funder

NONE

Publisher

Kocaeli University

Reference13 articles.

1. 1. Liang EF, Lim SZ, Tam WW, et al. The Effect of Methy-lphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression. Int J Environ Res Public Health. 2018;15:1789. doi: 10.3390/ijerph150817 89.

2. 2. Hennissen L, Bakker MJ, Banaschewski T, et al. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. CNS Drugs. 2017;31:199-215. doi:10.1007/s40263-017-0410-7.

3. 3. Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity dis-order: a systematic review of head-to-head studies. BMC Psychiatry. 2013;13:237. doi:10.1186/1471-244X-13-237.

4. 4. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107:E105. doi: 10.1542/peds.107.6.e105.

5. 5. Döpfner M, Ose C, Fischer R, Ammer R, Scherag A. Comparison of the efficacy of two different modi-fied release methylphenidate preparations for children and adolescents with attention deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet(®) retard and Concerta(®)—a randomized, controlled, double blind multicenter clinical cross-over trial. J Child Adolesc Psychopharmacol. 2011;21:445-54. doi: 10.1089/cap.2010.0082.